A European consortium led by Radboud university medical center has been awarded a European grant worth € 26 million for research into hypoglycemia. To curb the health risks and burden of disease caused by the ‘hypo’ (as it is known), in-depth research will be carried out by knowledge institutions, patient organizations and partners from industry.Diabetes is the most common chronic disease in the world. Europe alone has around 60 million patients, 10% of whom have type 1 diabetes. People with diabetes are unable to regulate the level of glucose in their blood automatically and use insulin to reduce high glucose (or sugar) levels. This is a very precise process. One of the side-effects of using insulin is developing a low concentration of glucose in the blood. This is known as hypoglycemia, or ‘hypo’ for short.
Important obstacleHypoglycemia is a serious side-effect that can cause symptoms such as confusion, cognitive problems and loss of consciousness. For this reason, patients and their families dread ‘hypos’. Hypoglycemia not only affects the patient’s quality of life, it also increases the risk of cardiovascular disease. Hypoglycemia is therefore an important obstacle when it comes to effective treatment for diabetes.
European grantThe Hypo-RESOLVE consortium, headed by doctors of internal medicine Bastiaan de Galan and Cees Tack, theme Mitochrondrial diseases, was recently awarded a grant worth € 26 million by the European Commission. The funding is for research designed to reduce the disease burden and consequences of hypoglycemia. The research project Hypo-RESOLVE (Hypoglycemia – Redefining SOLutions for better liVEs) was allocated a grant within the framework of the EU Horizon 2020-IMI program.
Understanding the hypoBastiaan de Galan: “We want to formulate the answers to questions that still go unanswered almost one hundred years after the discovery of insulin. One of our methods will be to set up a mega-database in which we combine 100 to 150 insulin trials to ascertain exactly how often hypoglycemia occurs. This will help us to define hypoglycemia and identify predictors in various populations. We can then use this information to derive practical standards and recommendations for pharmaceutical authorities, patient organizations and future research among patients.”
Better treatmentCees Tack: “We also intend to carry out fundamental and applied research to study and clarify the underlying mechanisms involved in hypoglycemia. This knowledge will enable us to develop new treatments for patients who don’t feel the warning signs of impending hypoglycemia. In addition, we will try to discover whether continuous glucose monitoring using a glucose sensor is worthwhile in practice. You mustn’t underestimate the psychological and economic impact of hypoglycemia on patients and their families. We want to define the extent of this impact as objectively as possible.”
The consortium hopes that this broad-based approach will ultimately achieve better quality of life for patients with diabetes who are treated with insulin.
Related news items
Step-up approach vs open necrosectomy for necrotizing pancreatitis18 April 2019
Another publication of the successful Dutch collaborative group on pancreatitis research with substantial contribution from Radboudumc researchers, Harry van Goor and Kees van Laarhoven.read more
Prophylactic antibiotics reduce hospitalisations and cost in head and neck cancer patients18 April 2019
In European journal of cancer Janneke Ham and colleagues showed that prophylactic antibiotics in locally advanced head and neck cancer patients treated with chemoradiotherapy did not reduce the incidence of (aspiration) pneumonias, but did reduce hospitalisations and tended to be cost-effective.read more
Nontuberculous mycobacteria and fungal co-infections Bonnie and Clyde?18 April 2019
In The European respiratory journal Jakko van Ingen and Sanne Zweijpfenning showed that 40% of patients diagnosed with nontuberculous mycobacterial pulmonary disease also meet diagnostic criteria for chronic pulmonary aspergillosis.read more
ESCMID award for groundbreaking studies on NTM disease18 April 2019
Jakko van Ingen received the ESCMID Young Investigator Award for his groundbreaking work on nontuberculous mycobacterial disease.read more
EU funded project BIOMAP led by Ellen van den Bogaard12 April 2019
Ellen van den Bogaard, theme Inflammatory diseases, leads the research on the experimental validation and functional analysis of identified biomarkers by using advanced organotypic skin models and receives a grant of €258,000.read more